Directory of Drugs: Osmoprep - sodium phosphate
FDA ALERT [5/2006]: A rare, but serious form of kidney failure has been associated with the use of oral sodium phosphate (OSP) products (e.g., Fleet Phospho-soda solution, Fleet Accu-Prep solution, and Visicol tablets) for bowel cleansing. No cases of kidney failure have been associated with a recently approved OSP product (OsmoPrep tablets) for bowel cleansing.
This is a summary of the most important information about oral sodium phosphate (OSP) bowel cleansing products. For details, talk to your healthcare professional.
What Are OSP Bowel Cleansing Products?
Bowel cleansing products are used to clean the stool out of your bowel before certain medical procedures, like colonoscopy.
Who Is at Most Risk for Kidney Failure with Use of OSP Bowel Cleansing Products?
You are at increased risk of developing kidney failure with the use of OSP bowel cleansing products if you have any of the following conditions:
What Are The Risks?
The following list includes the most common risks and side effects of OSP therapy. However, this list is not complete.
What Should I Tell My Healthcare Professional?
Before you use OSP bowel cleansing products , tell your healthcare professional if you:
Can Other Medicines Or Food Affect OSP Bowel Cleansing Products?
OSP bowel cleansing products and certain other medicines can interact with each other. Tell your healthcare professional about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how OSP bowel cleansing products work. Also, OSP bowel cleansing products may affect how your other medicines work. Know the medicines you take. Keep a list of them with you to show your healthcare professional.
What Else Should I Know About OSP Bowel Cleansing Products?
Bowel cleansing products work by causing you to loose large amounts of fluid through your bowel movements. Frequent, loose and liquid bowel movements are expected. It is very important that you replace this fluid to prevent dehydration. Drinking large amounts of clear liquids helps you replace the fluid you lose and helps clean your bowel for your procedure. Talk to your doctor about what you can drink to help lessen the chance of becoming dehydrated while using the OSP bowel cleansing products.
FDA ALERT [03/2006]: Acute phosphate nephropathy, a type of acute renal failure, is a rare, but serious adverse event associated with the use of oral sodium phosphates (OSP) for bowel cleansing. Documented cases of acute phosphate nephropathy include 21 patients who used an OSP solution (such as Fleet Phospho-soda or Fleet ACCU-PREP) and one patient who used OSP tablets (Visicol). No cases of acute phosphate nephropathy or acute renal failure have been associated with OsmoPrep, an OSP tablet bowel preparation recently approved. Individuals at increased risk of acute phosphate nephropathy include: those of advanced age, those with kidney disease or decreased intravascular volume, and those using medicines that affect renal perfusion or function [diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and possibly nonsteroidal anti-inflammatory drugs (NSAIDs)].
Acute phosphate nephropathy presents as acute renal failure with minimal proteinuria and a bland urine sediment in patients recently exposed to OSP. Renal biopsy reveals: acute and/or chronic renal tubular injury (depending on time to diagnosis), calcium-phosphate crystal deposition in the distal tubules and collecting ducts, and no other pattern of histological injury. These pathological findings are consistent with nephrocalcinosis.
Healthcare professionals should consider the following when choosing a bowel cleanser for their patients:
In September 2003, Desmeules et al published a case report of acute phosphate nephropathy followed by persistent renal insufficiency in a 71-year old woman who took 90 mL of OSP solution as a cathartic. 1
In November 2005, Markowitz et al published a case series study describing 21 biopsy-proven cases of acute phosphate nephropathy in patients who took OSP and had no history of hypercalcemia or superimposed renal pathology. 2 Twenty of these 21 cases of acute phosphate nephropathy occurred in patients who used OSP solution, and one case occurred in a patient who used OSP tablets (Visicol). Of the 21 cases, 17 occurred in females; 13 patients were age 62 years or older; 14 patients were using an ACE inhibitor or ARB; 4 patients were using a diuretic; and 3 patients were using a NSAID. Four patients had mildly elevated baseline serum creatinine levels between 1.3 and 1.7 mg/dL, and 17 patients had normal baseline creatinine levels. Eighteen patients were diagnosed with acute renal failure within two months of colonoscopy, and all were diagnosed within five months. At follow-up (mean 16.7 months post-biopsy), four patients were on hemodialysis (two with normal pre-procedure creatinine), and 17 patients had chronic renal failure with a mean serum creatinine of 2.4 mg/dL. 2
In addition to the published cases cited above, 10 unique cases of renal failure associated with use of OSP solution and 10 cases of renal failure associated with use of OSP tablets were identified through FDA’s Adverse Event Reporting System (AERS). Most of these cases did not have a renal biopsy or biopsy results were not available; therefore, the causes of renal failure were not clearly established in these patients.
OSP bowel cleansing involves a large phosphate load, fluid shifts, and decreased intravascular volume. Rarely, acute phosphate nephropathy and chronic impairment of renal function may occur after bowel cleansing with OSP products. In order to optimize safety for individual patients, healthcare providers should be familiar with the risk profiles of OSP products used for bowel cleansing.
For more detailed information about acute phosphate nephropathy, see the FDA Science Background Paper: Acute Phosphate Nephropathy and Renal Failure Associated With the Use of Oral Sodium Phosphate Bowel Cleansing Products.
Date created: May 5, 2006
© 2007 Directory of Drugs - reference guide to drugs - All rights reserved - Legal Notice